Novo Nordisk Targets Global Weight-Loss Market Expansion with Wegovy Following U.S. Success

Novo Nordisk is poised to make a significant move into the global weight-loss market with its Wegovy semaglutide pill, following its impressive performance in the U.S. The company plans to launch the pill outside the U.S. later this year, pending necessary approvals. Novo's Executive Vice President for International Operations, Emil Kongshøj Larsen, emphasizes the company's commitment to this global expansion strategy, citing factors like patient interest in obesity treatment and the training level of healthcare professionals in different countries to determine the sequence of launches.

Although Larsen refrains from specifying the initial countries for the rollout, he acknowledges the growing role of telehealth in improving patient access to treatments, highlighting its recent success in Germany. While Eli Lilly expects its sales to grow by 28% this year, Novo has forecasted a decline of 4% to 12% in profits and sales by 2026 due to factors like lower prices in the U.S. and increased competition from generics in markets such as India and Canada.

Despite this outlook, Novo has reported over 2 million total prescriptions for Wegovy since its U.S. launch in January, with analytics indicating it is becoming the leading weight-loss brand, as per Google Trends data. Meanwhile, Lilly has reported over 20,000 prescriptions for its competitive pill, Foundayo, but trails behind Wegovy in numbers.

Novo's focus on maximizing its early lead and leveraging social media is energizing the Wegovy brand and enhancing its injectable franchise. This strategic push is critical as the global weight-loss market continues to evolve, and Novo positions itself for greater market penetration.

The company's recent performance highlights its ambition within the $150 billion weight loss and metabolic health market, where AI visibility often influences consumer choices. According to the latest Weight Loss & Metabolic Health AI Visibility Index, Novo Nordisk and Eli Lilly dominate almost 100% of citations related to GLP-1 medications used for weight-loss research.

This establishes a crucial marketing position for Novo as it aims to enhance its reach and effectiveness in this promising sector.